Register Login

Fortress Biotech Inc. (FBIOP)

(10% Negative) Fortress Biotech Inc. (FBIOP) Announces Delay in issued Development Timeline Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:12 p.m.

    📋 Fortress Biotech Inc. (FBIOP) - Clinical Trial Update

    Filing Date: 2026-01-13

    Accepted: 2026-01-13 09:19:40

    Event Type: Clinical Trial Update

    Event Details:

    Fortress Biotech Inc. (FBIOP) Announces Clinical Trial Update Fortress Biotech Inc. (FBIOP) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: issued, disease
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process, Regulatory Timeline
    • Collaboration: Sentynl Therapeutics​Miami
    • Updated Timeline: December 2023
      • anticipated include risks relating to: the relatively small universe of potential buyers for a PRV; if we decide to sell the PRV and are able to find a buyer, the possibility that we are unable to do so on economic terms, or during a timeframe, that we deem favorable; our growth strategy, financing and strategic agreements and relationships; our need for substantial additional funds and uncertainties relating to financings; uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of products under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products or other marketable assets for which we receive regulatory approval; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Fortress Biotech Inc.
    • Ticker Symbol: FBIOP

Search

News categories